Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors

被引:49
|
作者
Faes, Seraina [1 ,2 ]
Duval, Adrian P. [1 ,2 ,6 ]
Planche, Anne [1 ,2 ]
Uldry, Emilie [1 ,2 ]
Santoro, Tania [1 ,2 ]
Pythoud, Catherine [1 ,2 ]
Stehle, Jean-Christophe [3 ,4 ]
Horlbeck, Janine [3 ,4 ]
Letovanec, Igor [4 ,5 ]
Riggi, Nicolo [4 ,5 ]
Demartines, Nicolas [1 ,2 ]
Dormond, Olivier [1 ,2 ]
机构
[1] CHU Vaudois, Lausanne Univ Hosp, Pavillon 4,Av Beaumont, CH-1011 Lausanne, Switzerland
[2] Univ Lausanne, Pavillon 4,Av Beaumont, CH-1011 Lausanne, Switzerland
[3] CHU Vaudois, Univ Lausanne Hosp, Mouse Pathol Facil, Lausanne, Switzerland
[4] Univ Lausanne, Lausanne, Switzerland
[5] CHU Vaudois, Univ Lausanne Hosp, Inst Pathol, Lausanne, Switzerland
[6] Ecole Polytech Fed Lausanne, Swiss Fed Inst Lausanne, Swiss Inst Expt Canc Res ISREC, Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
Tumor Microenvironment; Acidity; mTORC1; Rapamycin; Sodium Bicarbonate; Resistance Mechanisms; SODIUM-BICARBONATE; SYSTEMIC BUFFERS; CELL-GROWTH; PH; ACIDOSIS; PHOSPHORYLATION; CARCINOGENESIS; EVEROLIMUS; RESISTANCE; CARCINOMA;
D O I
10.1186/s12943-016-0562-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Blocking the mechanistic target of rapamycin complex-1 (mTORC1) with chemical inhibitors such as rapamycin has shown limited clinical efficacy in cancer. The tumor microenvironment is characterized by an acidic pH which interferes with cancer therapies. The consequences of acidity on the anti-cancer efficacy of mTORC1 inhibitors have not been characterized and are thus the focus of our study. Methods: Cancer cell lines were treated with rapamycin in acidic or physiological conditions and cell proliferation was investigated. The effect of acidity on mTORC1 activity was determined by Western blot. The anticancer efficacy of rapamycin in combination with sodium bicarbonate to increase the intratumoral pH was tested in two different mouse models and compared to rapamycin treatment alone. Histological analysis was performed on tumor samples to evaluate proliferation, apoptosis and necrosis. Results: Exposing cancer cells to acidic pH in vitro significantly reduced the anti-proliferative effect of rapamycin. At the molecular level, acidity significantly decreased mTORC1 activity, suggesting that cancer cell proliferation is independent of mTORC1 in acidic conditions. In contrast, the activation of mitogen-activated protein kinase (MAPK) or AKT were not affected by acidity, and blocking MAPK or AKT with a chemical inhibitor maintained an anti-proliferative effect at low pH. In tumor mouse models, the use of sodium bicarbonate increased mTORC1 activity in cancer cells and potentiated the anti-cancer efficacy of rapamycin. Combining sodium bicarbonate with rapamycin resulted in increased tumor necrosis, increased cancer cell apoptosis and decreased cancer cell proliferation as compared to single treatment. Conclusions: Taken together, these results emphasize the inefficacy of mTORC1 inhibitors in acidic conditions. They further highlight the potential of combining sodium bicarbonate with mTORC1 inhibitors to improve their anti-tumoral efficacy.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors
    Seraina Faes
    Adrian P. Duval
    Anne Planche
    Emilie Uldry
    Tania Santoro
    Catherine Pythoud
    Jean-Christophe Stehle
    Janine Horlbeck
    Igor Letovanec
    Nicolo Riggi
    Nicolas Demartines
    Olivier Dormond
    Molecular Cancer, 15
  • [2] mTORC1 and mTORC2 in cancer and the tumor microenvironment
    L C Kim
    R S Cook
    J Chen
    Oncogene, 2017, 36 : 2191 - 2201
  • [3] mTORC1 and mTORC2 in cancer and the tumor microenvironment
    Kim, L. C.
    Cook, R. S.
    Chen, J.
    ONCOGENE, 2017, 36 (16) : 2191 - 2201
  • [4] Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1
    Du, Heng
    Yang, Yu Chi
    Liu, Heng-Jia
    Yuan, Min
    Asara, John M.
    Wong, Kwok-Kin
    Henske, Elizabeth P.
    Singh, Mallika
    Kwiatkowski, David J.
    JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (21):
  • [5] Tumor Microenvironment Modulates Immunological Outcomes of Myeloid Cells with mTORC1 Disruption
    Ding, Chuanlin
    Sun, Xiaomin
    Wu, Caijun
    Hu, Xiaoling
    Zhang, Huang-ge
    Yan, Jun
    JOURNAL OF IMMUNOLOGY, 2019, 202 (05): : 1623 - 1634
  • [6] Novel inhibitors of mTORC1 and mTORC2
    Bhagwat, Shripad V.
    Crew, Andrew P.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (06) : 638 - 645
  • [7] Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1
    Du, Heng
    Yang, Yu Chi
    Liu, Heng-Jia
    Yuan, Min
    Asara, John
    Wong, Kwok-Kin
    Singh, Mallika
    Kwiatkowski, David
    CANCER RESEARCH, 2023, 83 (07)
  • [8] Aeovian raises cash for mTORC1 inhibitors
    Cross, Ryan
    CHEMICAL & ENGINEERING NEWS, 2019, 97 (40) : 13 - 13
  • [9] Treatment of Primary Aldosteronism With mTORC1 Inhibitors
    Trinh, Beckey
    Hepprich, Matthias
    Betz, Matthias J.
    Burkard, Thilo
    Cavelti-Weder, Claudia
    Seelig, Eleonora
    Meienberg, Fabian
    Kratschmar, Denise, V
    Beuschlein, Felix
    Reincke, Martin
    Odermatt, Alex
    Hall, Michael N.
    Donath, Marc Y.
    Swierczynska, Marta M.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (10): : 4703 - 4714
  • [10] Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth
    Bianca J. Lee
    Jacob A. Boyer
    G. Leslie Burnett
    Arun P. Thottumkara
    Nidhi Tibrewal
    Stacy L. Wilson
    Tientien Hsieh
    Abby Marquez
    Edward G. Lorenzana
    James W. Evans
    Laura Hulea
    Gert Kiss
    Hui Liu
    Dong Lee
    Ola Larsson
    Shannon McLaughlan
    Ivan Topisirovic
    Zhengping Wang
    Zhican Wang
    Yongyuan Zhao
    David Wildes
    James B. Aggen
    Mallika Singh
    Adrian L. Gill
    Jacqueline A. M. Smith
    Neal Rosen
    Nature Chemical Biology, 2021, 17 : 1065 - 1074